Amendment of the Misuse of Drugs Regulations 2001
2.—(1) The following amendments are made to the Misuse of Drugs Regulations 2001(1).
(2) In paragraph 1(a) of Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27)—
(a)after “Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)” insert “Brorphine”;
(b)after “Bufotenine” insert “Butonitazene”;
(c)after “Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)” insert “Clonitazene”;
(d)after “Concentrate of poppy-straw” insert “Cumyl-PeGaClone”;
(e)after “3-Dimethylheptyl-11-hydroxyhexahydrocannabinol” insert—
“Diphenidine
Ephenidine
Ethyleneoxynitazene”;
(f)after “Etizolam” insert—
“Etodesnitazene (etazene)
Etonitazene”;
(g)after “Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)” insert “Flunitazene”;
(h)after “Isopropylphenidate (IPP or IPPD)” insert “Isotonitazene”;
(i)after “Methcathinone” insert “Methoxyphenidine”;
(j)after “Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)” insert—
“Metodesnitazene (metazene)
Metonitazene”;
(k)after “Propylphenidate” insert “Protonitazene”;
(l)after “1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)” insert—
“N-Desethyl etonitazene
N-Desethylisotonitazene
N-Desethyl protonitazene”;
(m)after “4-Methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4’-DMAR)” insert—
“N-Piperidinyl-etonitazene (etonitazepipne)
N-Pyrrolidino-etonitazene (etoniazepyne)
N-Pyrrolidino protonitazene”.
(3) In paragraph 1 of Schedule 2 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 16A, 18, 19, 20, 21, 23, 26 and 27) omit “Clonitazene” and “Etonitazene”.
(4) In paragraph 1 of Part 1 of Schedule 4 (which specifies controlled drugs subject to the requirements of regulations 22, 23, 26 and 27) after “Pyrovalerone” insert “Remimazolam”.
S.I. 2001/3998, amended by S.I. 2009/3136, 2015/231 and 2017/631. There are other amending instruments, but none are relevant.